ERAS

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

Key Dates and Disclosure Events Shareholders Need to Know: From J.P. Morgan Conference Claims to Patent Infringement Letter and Patient Death, a 15-Month Sequence of Events Cost ERAS Investors $11.59 Per Share NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Erasca, Inc. (NASDAQ: ERAS) to contact the firm.

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) investors of the  August 10, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Erasca Class Action Lawsuit : Do you, or did you, own shares of Erasca, Inc. (NASDAQ: ERAS)?

Philadelphia, Pennsylvania--(Newsfile Corp. - July 29, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "Company") on behalf of investors who purchased or acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Erasca securities during the Class Period may, no later than August 10, 2026, seek to be appointed as a lead plaintiff representative of the class.

New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) on behalf of investors that purchased or otherwise acquired Erasca securities between January 14, 2025 and April 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Erasca and have suffered losses, you may CLICK HERE to contact us.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 29, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK and NEW ORLEANS, July 28, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Erasca, Inc. (“Erasca” or the “Company”) (NasdaqGS: ERAS) of a class action securities lawsuit.

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

New York, New York--(Newsfile Corp. - July 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline. SO WHAT: If you purchased Erasca common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.